Published in J Natl Cancer Inst on October 18, 2011
Hypoxia, notch signalling, and prostate cancer. Nat Rev Urol (2013) 2.24
The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis (2013) 1.50
Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov (2013) 1.25
Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors? J Natl Cancer Inst (2012) 1.19
Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems. Nat Commun (2012) 0.96
High NOTCH activity induces radiation resistance in non small cell lung cancer. Radiother Oncol (2013) 0.87
HDAC5 promotes colorectal cancer cell proliferation by up-regulating DLL4 expression. Int J Clin Exp Med (2015) 0.83
Targeting Notch to overcome radiation resistance. Oncotarget (2016) 0.82
Dll4-notch signalling blockade synergizes combined ultrasound-stimulated microbubble and radiation therapy in human colon cancer xenografts. PLoS One (2014) 0.81
Pleiotropic roles of Notch signaling in normal, malignant, and developmental hematopoiesis in the human. EMBO Rep (2014) 0.81
Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells. Int J Oncol (2016) 0.80
miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). Oncotarget (2015) 0.80
Delta-like ligand 4 (Dll4) predicts the prognosis of clear cell renal cell carcinoma, and anti-Dll4 suppresses tumor growth in vivo. Int J Clin Exp Pathol (2014) 0.77
Simultaneous targeted activation of Notch1 and Vhl-disruption in the kidney proximal epithelial tubular cells in mice. Sci Rep (2016) 0.75
Nox2 contributes to the arterial endothelial specification of mouse induced pluripotent stem cells by upregulating Notch signaling. Sci Rep (2016) 0.75
Pea3 expression promotes the invasive and metastatic potential of colorectal carcinoma. World J Gastroenterol (2014) 0.75
Re: Delta-like ligand 4-Notch blockade and tumor radiation response. J Natl Cancer Inst (2012) 0.75
Targeting progastrin enhances radiosensitization of colorectal cancer cells. Oncotarget (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 10.28
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol (2005) 6.44
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23
Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem (2004) 5.05
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell (2002) 4.82
A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One (2009) 3.86
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine (2011) 3.79
How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 3.77
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell (2010) 3.27
microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res (2011) 3.25
NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol (2003) 3.19
Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol (2010) 3.07
Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res (2003) 2.93
Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood (2005) 2.91
Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia (2002) 2.90
HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell (2005) 2.82
Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res (2006) 2.68
Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res (2009) 2.58
Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev (2007) 2.56
Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol (2011) 2.45
Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab (2012) 2.43
Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res (2002) 2.31
Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res (2007) 2.31
Activating transcription factor 4. Int J Biochem Cell Biol (2007) 2.26
HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol (2010) 2.24
Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res (2005) 2.16
Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res (2002) 2.13
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res (2003) 2.08
Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res (2004) 2.07
Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res (2007) 2.06
MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One (2010) 2.05
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res (2002) 2.05
The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res (2009) 2.03
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res (2003) 1.99
hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer (2010) 1.95
Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med (2008) 1.93
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res (2006) 1.92
Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol (2003) 1.92
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol (2003) 1.92
Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle (2004) 1.90
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res (2002) 1.84
Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res (2004) 1.83
New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood (2010) 1.82
HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res (2005) 1.81
MicroRNA-10b and breast cancer metastasis. Nature (2008) 1.80
Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes (2009) 1.78
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res (2011) 1.78
Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene (2005) 1.78
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci (Landmark Ed) (2009) 1.76
Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res (2007) 1.75
Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res (2004) 1.75
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res (2002) 1.74
Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med (2009) 1.74
Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group. J Clin Oncol (2006) 1.74
Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys (2002) 1.74
Tumor cell alpha3beta1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol (2004) 1.72
Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One (2011) 1.72
Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood (2009) 1.70
Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys (2003) 1.68
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res (2002) 1.68
Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression. J Mol Med (Berl) (2006) 1.66
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest (2004) 1.65
A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown. Cancer Res (2010) 1.65
Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia (2005) 1.62
Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol (2007) 1.61
Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res (2003) 1.60
Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics (2008) 1.60
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res (2004) 1.59
Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res (2006) 1.58
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Clin Invest (2012) 1.57
GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer (2003) 1.56
A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res (2004) 1.56
Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol (2003) 1.56
A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo. J Nucl Med (2013) 1.55
Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol (2005) 1.55
Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem (2002) 1.53
The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem (2009) 1.53
Histological quantitation of tumour angiogenesis. APMIS (2004) 1.52
Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol (2004) 1.52
Angiogenesis in endocrine tumors. Endocr Rev (2003) 1.50
Overexpression of POLQ confers a poor prognosis in early breast cancer patients. Oncotarget (2010) 1.49
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res (2004) 1.48
Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. Stem Cells (2006) 1.47
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res (2011) 1.46
Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res (2003) 1.46
p21-activated kinase 1: PAK'ed with potential. Oncotarget (2011) 1.44
Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol (2005) 1.43
Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res (2005) 1.41